Biocon Limited has announced a significant regulatory milestone with its wholly owned subsidiary Biocon Pharma Limited receiving approval from the U.S. Food and Drug Administration (U.S. FDA) for Everolimus Tablets for Oral Suspension. The company notified stock exchanges about this development on January 12, 2026.

FDA Approval Details

The U.S. FDA has approved Biocon Pharma Limited's Abbreviated New Drug Application (ANDA) for Everolimus Tablets for Oral Suspension across three different strengths. The approval encompasses a comprehensive range of dosing options for healthcare providers.

Therapeutic Applications

The approved Everolimus Tablets for Oral Suspension serve specific medical indications related to Tuberous Sclerosis Complex (TSC). The medication addresses two distinct patient populations with different age requirements and treatment purposes.

Primary Indications:

• SEGA Treatment: For adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex who have Subependymal Giant Cell Astrocytoma
• Seizure Management: For adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures

Strategic Impact

According to the company's notification to stock exchanges, this FDA approval will further strengthen Biocon's portfolio of vertically integrated drug products. The approval represents an expansion of the company's presence in the U.S. pharmaceutical market through its specialized oncology and rare disease treatment offerings.

The regulatory milestone demonstrates Biocon Pharma Limited's capability to successfully navigate the complex U.S. FDA approval process for specialized therapeutic products. This achievement adds to the company's growing portfolio of approved pharmaceutical products in international markets.